Cell-surface central nervous system autoantibodies: Clinical relevance and emerging paradigms

Annals of Neurology

Volumn 76, Issue 2, 2014, Pages 168-184

  Irani, Sarosh R ^a,b   Gelfand, Jeffrey M ^b   Al Diwani, Adam ^a   Vincent, Angela ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR ANTIBODY; ALPHA AMINO 3 HYDROXY 5 METHYLISOXAZOLE 4 PROPIONIC ACID RECEPTOR ANTIBODY; AQUAPORIN 4 ANTIBODY; AUTOANTIBODY; CONTACTIN ASSOCIATED PROTEIN 2 ANTIBODY; DIPEPTIDYL PEPTIDASE IV RELATED PROTEIN ANTIBODY; DOPAMINE 2 RECEPTOR ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; GLYCINE ANTIBODY; GLYCINE RECEPTOR ANTIBODY; LEUCINE RICH GLIOMA INACTIVATED 1 ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; NEUROGLIAL SURFACE DIRECTED ANTIBODY; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL COMPLEX ANTIBODY; MEMBRANE PROTEIN;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; BRAIN DISEASE; CELL SURFACE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID LEVEL; COGNITIVE DEFECT; DEMENTIA; DEMYELINATING DISEASE; ENCEPHALITIS; EPILEPSY; HUMAN; IMMUNOASSAY; IMMUNOTHERAPY; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPECTRUM; IMMUNOLOGY;

AUTOANTIBODIES; CENTRAL NERVOUS SYSTEM; HUMANS; MEMBRANE PROTEINS; NERVOUS SYSTEM DISEASES;

EID: 84907598204     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24200     Document Type: Review

References (166)

1. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140.
2. McKeon A, Pittock SJ,. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 2011; 122: 381-400.
3. Vincent A, Bien CG, Irani SR, Waters P,. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011; 10: 759-772.
4. Leypoldt F, Wandinger KP,. Paraneoplastic neurological syndromes. Clin Exp Immunol 2014; 175: 336-348.
5. Tanaka M, Tanaka K, Shinozawa K, et al. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 1998; 161: 88-90.
6. Vincent A, Lily O, Palace J,. Pathogenic autoantibodies to neuronal proteins in neurological disorders. J Neuroimmunol 1999; 100: 169-180.
7. Lancaster E, Dalmau J,. Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 2012; 8: 380-390.
8. Zuliani L, Graus F, Giometto B, et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012; 83: 638-645.
9. Fukata Y, Adesnik H, Iwanaga T, et al. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science 2006; 313: 1792-1795.
10. Irani SR, Vincent A,. Autoimmune encephalitis-new awareness, challenging questions. Discov Med 2011; 11: 449-458.
11. Irani SR, Vincent A,. The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arq Neuropsiquiatr 2012; 70: 300-304.
12. Granerod J, Cousens S, Davies NW, et al. New estimates of incidence of encephalitis in England. Emerg Infect Dis 2013; 19 (9).
13. Asgari N, Lillevang ST, Skejoe HP, et al. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011; 76: 1589-1595.
14. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131: 2553-2563.
15. Malter MP, Helmstaedter C, Urbach H, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010; 67: 470-478.
16. Vincent A,. Stiff, twitchy or wobbly: are GAD antibodies pathogenic? Brain 2008; 131: 2536-2537.
17. Boronat A, Sabater L, Saiz A, et al. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011; 76: 795-800.
18. McKeon A, Martinez-Hernandez E, Lancaster E, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol 2013; 70: 44-50.
19. Chang T, Alexopoulos H, McMenamin M, et al. Neuronal surface and glutamic acid decarboxylase autoantibodies in nonparaneoplastic stiff person syndrome. JAMA Neurol 2013; 70: 1140-1149.
20. Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012; 72: 241-255.
21. Turner MR, Irani SR, Leite MI, et al. Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies. Neurology 2011; 77: 439-443.
22. Pruss H, Finke C, Holtje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012; 72: 902-911.
23. Machado S, Pinto AN, Irani SR,. What should you know about limbic encephalitis? Arq Neuropsiquiatr 2012; 70: 817-822.
24. Geschwind MD, Shu H, Haman A, et al. Rapidly progressive dementia. Ann Neurol 2008; 64: 97-108.
25. Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010; 10: 835-844.
26. Chitravas N, Jung RS, Kofskey DM, et al. Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol 2011; 70: 437-444.
27. Gable MS, Sheriff H, Dalmau J, et al. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012; 54: 899-904.
28. Rosenbloom MH, Smith S, Akdal G, Geschwind MD,. Immunologically mediated dementias. Curr Neurol Neurosci Rep 2009; 9: 359-367.
29. Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001; 50: 73-78.
30. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127: 701-712.
31. Thieben MJ, Lennon VA, Boeve BF, et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004; 62: 1177-1182.
32. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133: 2734-2748.
33. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9: 776-785.
34. Geschwind MD, Tan KM, Lennon VA, et al. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease. Arch Neurol 2008; 65: 1341-1346.
35. Dhamija R, Renaud DL, Pittock SJ, et al. Neuronal voltage-gated potassium channel complex autoimmunity in children. Pediatr Neurol 2011; 44: 275-281.
36. Haberlandt E, Bast T, Ebner A, et al. Limbic encephalitis in children and adolescents. Arch Dis Child 2011; 96: 186-191.
37. Hacohen Y, Wright S, Waters P, et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry 2013; 84: 748-755.
38. Suleiman J, Brenner T, Gill D, et al. VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology 2011; 76: 1252-1255.
39. Suleiman J, Brilot F, Lang B, et al. Autoimmune epilepsy in children: case series and proposed guidelines for identification. Epilepsia 2013; 54: 1036-1045.
40. Jeffery OJ, Lennon VA, Pittock SJ, et al. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 2013; 81: 882-887.
41. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65: 424-434.
42. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9: 67-76.
43. Somers KJ, Lennon VA, Rundell JR, et al. Psychiatric manifestations of voltage-gated potassium-channel complex autoimmunity. J Neuropsychiatry Clin Neurosci 2011; 23: 425-433.
44. Tan KM, Lennon VA, Klein CJ, et al. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008; 70: 1883-1890.
45. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098.
46. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133: 1655-1667.
47. Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J,. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 2013; 70: 1133-1139.
48. Zandi MS, Irani SR, Lang B, et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011; 258: 686-688.
49. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36.
50. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74.
51. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009; 66: 11-18.
52. Hammer C, Stepniak B, Schneider A, et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry. 2013 Sep 3. doi: 10.1038/mp.2013.110. [Epub ahead of print]
53. Steiner J, Walter M, Glanz W, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013; 70: 271-278.
54. Dale RC, Merheb V, Pillai S, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 2012; 135: 3453-3468.
55. Graus F, Boronat A, Xifro X, et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010; 74: 857-859.
56. Shorvon SD,. The etiologic classification of epilepsy. Epilepsia 2011; 52: 1052-1057.
57. Majoie HJ, de Baets M, Renier W, et al. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res 2006; 71: 135-141.
58. McKnight K, Jiang Y, Hart Y, et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005; 65: 1730-1736.
59. Peltola J, Kulmala P, Isojarvi J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000; 55: 46-50.
60. Brenner T, Sills GJ, Hart Y, et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 2013; 54: 1028-1035.
61. Lilleker JB, Jones MS, Mohanraj R,. VGKC complex antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure 2013; 22: 776-779.
62. Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012; 69: 582-593.
63. Bien CG, Elger CE,. Limbic encephalitis: a cause of temporal lobe epilepsy with onset in adult life. Epilepsy Behav 2007; 10: 529-538.
64. Bien CG, Schulze-Bonhage A, Deckert M, et al. Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology 2000; 55: 1823-1828.
65. Irani SR, Bien CG, Lang B,. Autoimmune epilepsies. Curr Opin Neurol 2011; 24: 146-153.
66. Barajas RF, Collins DE, Cha S, Geschwind MD,. Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia 2010; 51: 473-477.
67. Irani SR, Buckley C, Vincent A, et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 2008; 71: 1647-1648.
68. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69: 892-900.
69. Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013; 136: 3151-3162.
70. Yoo JY, Hirsch LJ,. Limbic encephalitis associated with anti-voltage-gated potassium channel complex antibodies mimicking Creutzfeldt-Jakob disease. JAMA Neurol 2014; 71: 79-82.
71. Plantone D, Renna R, Grossi D, et al. Teaching NeuroImages: basal ganglia involvement in facio-brachial dystonic seizures associated with LGI1 antibodies. Neurology 2013; 80: e183-e184.
72. Naasan G, Irani SR, Bettcher BM, et al. Episodic bradycardia: a neurocardiac prodrome to VGKC-complex/LGI1-antibody encephalitis. JAMA Neurol (in press).
73. Dale RC, Heyman I, Giovannoni G, Church AW,. Incidence of anti-brain antibodies in children with obsessive-compulsive disorder. Br J Psychiatry 2005; 187: 314-319.
74. Edwards MJ, Trikouli E, Martino D, et al. Anti-basal ganglia antibodies in patients with atypical dystonia and tics: a prospective study. Neurology 2004; 63: 156-158.
75. Dale RC, Irani SR, Brilot F, et al. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009; 66: 704-709.
76. Stamelou M, Plazzi G, Lugaresi E, et al. The distinct movement disorder in anti-NMDA receptor encephalitis may be related to status dissociatus: a hypothesis. Mov Disord 2012; 27: 1360-1363.
77. Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J,. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 2013; 28: 543-547.
78. Hacohen Y, Deiva K, Pettingill P, et al. N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord 2014; 29: 90-96.
79. Hacohen Y, Dlamini N, Hedderly T, et al. N-methyl-D-aspartate receptor antibody-associated movement disorder without encephalopathy. Dev Med Child Neurol 2014; 56: 190-193.
80. Mohammad SS, Sinclair K, Pillai S, et al. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-aspartate receptor or dopamine-2 receptor. Mov Disord 2014; 29: 117-122.
81. Leypoldt F, Titulaer MJ, Aguilar E, et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology 2013; 81: 1637-1639.
82. Hoftberger R, Armangue T, Leypoldt F, et al. Clinical neuropathology practice guide 4-2013: post-herpes simplex encephalitis: N-methyl-Daspartate receptor antibodies are part of the problem. Clin Neuropathol 2013; 32: 251-254.
83. Barker RA, Revesz T, Thom M, et al. Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 1998; 65: 633-640.
84. Meinck HM, Thompson PD,. Stiff man syndrome and related conditions. Mov Disord 2002; 17: 853-866.
85. McKeon A, Robinson MT, McEvoy KM, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol 2012; 69: 230-238.
86. Shaw PJ,. Stiff-man syndrome and its variants. Lancet 1999; 353: 86-87.
87. Raju R, Rakocevic G, Chen Z, et al. Autoimmunity to GABAA-receptor- associated protein in stiff-person syndrome. Brain 2006; 129: 3270-3276.
88. Butler MH, Hayashi A, Ohkoshi N, et al. Autoimmunity to gephyrin in stiff-man syndrome. Neuron 2000; 26: 307-312.
89. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008; 71: 1291-1292.
90. Mas N, Saiz A, Leite MI, et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 2011; 82: 1399-1401.
91. Stern WM, Howard R, Chalmers RM, et al. Glycine receptor antibody mediated progressive encephalomyelitis with rigidity and myoclonus (PERM): a rare but treatable neurological syndrome. Pract Neurol 2014; 14: 123-127.
92. Balint B, Jarius S, Nagel S, et al. Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology 2014; 82: 1521-1528.
93. Becker EB, Zuliani L, Pettingill R, et al. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry 2012; 83: 437-440.
94. Tofaris GK, Irani SR, Cheeran BJ, et al. Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis. Neurology 2012; 79: 195-196.
95. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
96. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130: 1194-1205.
97. Kim SH, Kim W, Li XF, et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 2012; 18: 1480-1483.
98. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69: 239-245.
99. Waters P, Vincent A,. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 2008; 15: 99-105.
100. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012; 78: 665-671; discussion 669.
101. Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011; 76: 1229-1237.
102. Newey CR, Bermel RA,. Fulminant cerebral demyelination in neuromyelitis optica. Neurology 2011; 77: 193.
103. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63: 390-396.
104. Wingerchuk DM,. Neuromyelitis optica spectrum disorders. Continuum (Minneap Minn) 2010; 16: 105-121.
105. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
106. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17: 1019-1032.
107. Klein CJ, Lennon VA, Aston PA, et al. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology 2012; 79: 1136-1144.
108. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012; 79: 1273-1277.
109. Rostasy K, Mader S, Hennes EM, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013; 19: 1052-1059.
110. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474-481.
111. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71: 276-283.
112. Di Pauli F, Mader S, Rostasy K, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011; 138: 247-254.
113. Hacohen Y, Absoud M, Woodhall M, et al. Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. J Neurol Neurosurg Psychiatry 2014; 85: 456-461.
114. Zoccarato M, Saddi MV, Serra G, et al. Aquaporin-4 antibody neuromyelitis optica following anti-NMDA receptor encephalitis. J Neurol 2013; 260: 3185-3187.
115. Kruer MC, Koch TK, Bourdette DN, et al. NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology 2010; 74: 1473-1475.
116. Titulaer MJ, Hoftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 75: 411-428.
117. Karadottir R, Cavelier P, Bergersen LH, Attwell D,. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005; 438: 1162-1166.
118. Olberg H, Haugen M, Storstein A, Vedeler CA,. Neurological manifestations related to level of voltage-gated potassium channel antibodies. J Neurol Neurosurg Psychiatry 2013; 84: 941-943.
119. Paterson RW, Zandi MS, Armstrong R, et al. Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry 2014; 85: 625-630.
120. Angus-Leppan H, Rudge P, Mead S, et al. Autoantibodies in sporadic Creutzfeldt-Jakob disease. JAMA Neurol 2013; 70: 919-922.
121. Irani SR, Vincent A,. NMDA receptor antibody encephalitis. Curr Neurol Neurosci Rep 2011; 11: 298-304.
122. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13: 167-177.
123. Suh-Lailam BB, Haven TR, Copple SS, et al. Anti-NMDA-receptor antibody encephalitis: performance evaluation and laboratory experience with the anti-NMDA-receptor IgG assay. Clin Chim Acta 2013; 421: 1-6.
124. Carvajal-González A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014 Jun 20. pii: awu142. [Epub ahead of print]
125. Chang T, Alexopoulos H, Pettingill P, et al. Immunization against GAD induces antibody binding to GAD-independent antigens and brainstem GABAergic neuronal loss. PLoS One 2013; 8: e72921.
126. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007; 25: 2295-2305.
127. Smith JH, Dhamija R, Moseley BD, et al. N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus: treatment response to plasmapheresis. Arch Neurol 2011; 68: 1069-1072.
128. Nunez-Enamorado N, Camacho-Salas A, Belda-Hofheinz S, et al. Fast and spectacular clinical response to plasmapheresis in a pediatric case of anti-NMDA encephalitis [in Spanish]. Rev Neurol 2012; 54: 420-424.
129. Pham HP, Daniel-Johnson JA, Stotler BA, et al. Therapeutic plasma exchange for the treatment of anti-NMDA receptor encephalitis. J Clin Apher 2011; 26: 320-325.
130. Ehrlich S, Fassbender CM, Blaes C, et al. Therapeutic apheresis for autoimmune encephalitis: a nationwide data collection [in German]. Nervenarzt 2013; 84: 498-507.
131. Jacob A, McKeon A, Nakashima I, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013; 84: 922-930.
132. Hansen HC, Klingbeil C, Dalmau J, et al. Persistent intrathecal antibody synthesis 15 years after recovering from anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurol 2013; 70: 117-119.
133. Labate A, Quattrone A, Dalmau J, Gambardella A,. Anti-N-methyl-D- aspartate-glutamic-receptor encephalitis presenting as paroxysmal exercise-induced foot weakness. Mov Disord 2013; 28: 820-822.
134. Mackay G, Ahmad K, Stone J, et al. NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. J Neurol 2012; 259: 1979-1981.
135. Outteryck O, Baille G, Hodel J, et al. Extensive myelitis associated with anti-NMDA receptor antibodies. BMC Neurol 2013; 13: 211.
136. Dahm L, Ott C, Steiner J, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014 May 23. doi: 10.1002/ana.24189. [Epub ahead of print]
137. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-165.
138. Sato DK, Nakashima I, Takahashi T, et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 2013; 80: 2210-2216.
139. Lim YM, Pyun SY, Kang BH, et al. Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler 2013; 19: 1216-1218.
140. Kaplan AA,. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008; 52: 1180-1196.
141. Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007; 13: 968-974.
142. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77: 659-666.
143. Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 2013; 84: 918-921.
144. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66: 1128-1133.
145. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270-1272.
146. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443-1448.
147. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011; 76: 1310-1315.
148. Kim SH, Kim W, Park MS, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011; 68: 473-479.
149. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006; 63: 957-963.
150. Araki M, Aranami T, Matsuoka T, et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013; 23: 827-831.
151. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013; 12: 554-562.
152. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy. JAMA Neurol 2014; 71: 324-330.
153. Wong SH, Saunders MD, Larner AJ, et al. An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J Neurol Neurosurg Psychiatry 2010; 81: 1167-1169.
154. Jaben EA, Winters JL,. Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage-gated potassium channels: a report of five cases and review of the literature. J Clin Apher 2012; 27: 267-273.
155. Frisch C, Malter MP, Elger CE, Helmstaedter C,. Neuropsychological course of voltage-gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis. Eur J Neurol 2013; 20: 1297-1304.
156. Irani SR, Gelfand JM, Bettcher BM, et al. Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy. JAMA Neurol. 2014 May 19. doi: 10.1001/jamaneurol.2014.463. [Epub ahead of print]
157. Vincent A, Irani SR,. Caspr2 antibodies in patients with thymomas. J Thorac Oncol 2010; 5: S277-S280.
158. Iizuka T, Leite MI, Lang B, et al. Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. J Neurol 2012; 259: 1566-1573.
159. Pittock SJ, Lennon VA,. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 2008; 65: 629-632.
160. Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J,. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 2013; 70: 1133-1139.
161. Rubio-Agusti I, Dalmau J, Sevilla T, et al. Isolated hemidystonia associated with NMDA receptor antibodies. Mov Disord 2011; 26: 351-352.
162. Niehusmann P, Dalmau J, Rudlowski C, et al. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 2009; 66: 458-464.
163. Tuzun E, Kinay D, Hacohen Y, et al. Guillain-Barre-like syndrome associated with lung adenocarcinoma and CASPR2 antibodies. Muscle Nerve 2013; 48: 836-837.
164. Ekizoglu E, Tuzun E, Woodhall M, et al. Investigation of neuronal autoantibodies in two different focal epilepsy syndromes. Epilepsia 2014; 55: 414-422.
165. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009; 72: 712-717.
166. Huppke P, Rostasy K, Karenfort M, et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler 2013; 19: 941-946.